Stephan Willems - LAA occlusion should be for (N)OAC in-tolerant patients. Not everyone!

Posted on 19-02-16

About this lecture

Debate: Is LAA occlusion an alternative to oral anticoagulation in low bleeding risk patients? 

Antagonist:
LAA occlusion should be considered for (N)OAC in-tolerant patients primarily. NOT for everyone!

Subjects related to this video

Clinical Evidence Indications & Referral

Related video's

David Hildick Smith - What’s new: clinical data published and presented since last year

New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Clinical Evidence Scientific Meetings

Matthew Price - What’s new: cost effectiveness and health economics

Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
Clinical Evidence Scientific Meetings

John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?

John Camm, UK vs Hans Christoph Diener, DEU    Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!
Clinical Evidence Indications & Referral Patient Information
+1
To lecture overview